Critical Contrast: ProKidney (NASDAQ:PROK) versus BeOne Medicines (NASDAQ:ONC)

ProKidney (NASDAQ:PROK) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Insider & Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ProKidney and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
BeOne Medicines	8.94%	12.06%	6.69%

Earnings & Valuation

This table compares ProKidney and BeOne Medicines”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890,000.00	573.31	-$68.99 million	($0.53)	-3.19
BeOne Medicines	$5.74 billion	5.90	$286.93 million	$4.47	69.07

BeOne Medicines has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for ProKidney and BeOne Medicines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2	1	4	1	2.50
BeOne Medicines	1	2	11	1	2.80

ProKidney currently has a consensus price target of $7.40, indicating a potential upside of 337.87%. BeOne Medicines has a consensus price target of $389.15, indicating a potential upside of 26.05%. Given ProKidney’s higher possible upside, analysts clearly believe ProKidney is more favorable than BeOne Medicines.

Risk and Volatility

ProKidney has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

Summary

BeOne Medicines beats ProKidney on 9 of the 14 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.